Nanomerics is an award winning speciality pharmaceutical company. Nanomerics was was founded by Prof Ijeoma F Uchegbu and Prof Andreas G Schätzlein in 2010 to develop know-how originally discovered in their laboratories at the University of Glasgow, Strathclyde University, the School of Pharmacy and University College London.
Nanomerics operates from its own research laboratories integrated into the St Marks NHS hospital site in North London.
Nanomerics has developed an extensive intellectual property (IP) portfolio and has in-licensed additional IP. Nanomerics has out-licensed some of its programs in regional or global deals. In addition to its own development program Nanomerics is also working with a number of partners to apply enhanced delivery strategies to their products.
Meet The Team
Professor of Translational Therapeutics, Dr med vet
Chief Executive Officer
Andreas, has over 30 years experience in medicines development in industry and academia. Trained as a veterinary surgeon, Andreas joined the Munich start-up IDEA to commercialise transdermal 'transfersome' drug delivery technology. He later joined academia, becoming leader of the CRUK's Beatson Laboratories ‘Experimental Therapeutics and Gene Medicines’ Group. Andreas holds a chair in Translational Therapeutics at University College London. He is a co-founder and the Chief Executive Officer of Nanomerics.
Professor of Pharmaceutical Nanoscience, PhD
Chief Scientific Officer
Ijeoma is a multi-award winning nanotechnology scientist and Fellow of the Academy of Medical Sciences. Ijeoma is the founding Chief Scientific Officer (CSO) of Nanomerics. In addition, Ijeoma holds a chair in Pharmaceutical Nanosciences at University College London. She has received a number of awards, notably the UK’s Women of Outstanding Achievement Award (2007) in Science Engineering and Technology.
Alan has more than 40 years of experience in senior positions in the pharmaceutical industry (Wellcome, Upjohn, Glaxo), and served as Vice President Discovery Medicine for the Psychiatry Centre of Excellence Drug Discovery at GSK.
Alan has been involved with the development of hundreds of compounds, leading to more than 300 first in human studies, and to the successful launch of of more than 40 commercial products.
Alan also has a particular interest in the pre-clinical to clinical translation in the neuroscience and pain, an area in which he has also widely published.
Andrea has over 30 years of wide ranging experience with innovative businesses both as an investor and entrepreneur. His background in design and innovation (Delft University of Technology and SUC at Buffalo NY) has led him to senior executive and strategic roles in a range of technology driven companies. Andrea is also an individual investor in Nanomerics.
Northwick Park and St Mark’s Hospital,
Y Block, Watford Road,
Harrow, Middlesex, HA1 3UJ
(access via St Mark’s Hospital main entrance)
Nearest Underground Station: Northwick Park (Metropolitan Line)
Nearest National Rail Station: Kenton (London Euston to Watford Junction Line)
Local Bus Routes: No 186, 223, H9, H10, H14, H18, H19, N18